米托蒽醌治疗恶性黑色素瘤
Mitoxantrone in malignant melanoma.
作者信息
Presant C A, Gams R, Bartolucci A
出版信息
Cancer Treat Rep. 1984 Jun;68(6):903-5.
PMID:6733704
Abstract
Twenty-nine patients with metastatic malignant melanoma without prior chemotherapy and 36 patients refractory to prior chemotherapy received mitoxantrone (5 mg/m2/week). No patient achieved a partial response. The dose-limiting toxic effect was granulocytopenia. Mitoxantrone is ineffective in malignant melanoma.
摘要
29例未经前期化疗的转移性恶性黑色素瘤患者和36例对前期化疗难治的患者接受了米托蒽醌（5毫克/平方米/周）治疗。无一例患者达到部分缓解。剂量限制性毒性作用为粒细胞减少。米托蒽醌对恶性黑色素瘤无效。
相似文献
1
Mitoxantrone in malignant melanoma.米托蒽醌治疗恶性黑色素瘤
Cancer Treat Rep. 1984 Jun;68(6):903-5.
2
A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.二羟基蒽二酮（DHAD，米托蒽醌，NSC 301739）用于晚期恶性黑色素瘤的II期研究。
Invest New Drugs. 1986;4(1):53-6. doi: 10.1007/BF00172017.
3
Phase II trial of 4'-epi-doxorubicin in patients with advanced malignant melanoma.4'-表阿霉素用于晚期恶性黑色素瘤患者的II期试验。
Cancer Treat Rep. 1984 Apr;68(4):679-80.
4
Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.转移性黑色素瘤的化疗：安吖啶、米托蒽醌和比生群的II期研究。
Eur J Cancer Clin Oncol. 1986 Jan;22(1):97-100. doi: 10.1016/0277-5379(86)90347-0.
5
[Phase II study of mitoxantrone for hematologic malignancies].米托蒽醌治疗血液系统恶性肿瘤的II期研究
Gan To Kagaku Ryoho. 1983 Nov;10(11):2399-402.
6
[Phase II study of mitoxantrone].米托蒽醌的II期研究
Gan To Kagaku Ryoho. 1984 Aug;11(8):1649-54.
7
Mitoxantrone for treatment of patients with refractory small cell carcinoma of the lung: a Southwest Oncology Group Study.
Cancer Treat Rep. 1983 Apr;67(4):403-4.
8
Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.4'-(9-吖啶基氨基)甲磺酰间茴香胺（AMSA）治疗转移性黑色素瘤的II期研究。
Cancer Clin Trials. 1980 Summer;3(2):111-4.
9
Phase II trial of mitoxantrone in advanced colorectal cancer.米托蒽醌治疗晚期结直肠癌的II期试验。
Cancer Treat Rep. 1982 Nov;66(11):1995-6.
10
Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot.1,4 - 二羟基 - 5,8 - 双（（2 - （（2 - 羟乙基）氨基）乙基）氨基）- 9,10 - 蒽二酮二盐酸盐（NSC 301739，DHAD）用于转移性恶性黑色素瘤患者的II期试验。西南肿瘤协作组的一项试点研究。
Invest New Drugs. 1985;3(1):67-9. doi: 10.1007/BF00176827.
引用本文的文献
1
Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma.纳米载体介导的化疗免疫治疗抑制促结缔组织增生性黑色素瘤的进展并诱导肿瘤休眠。
ACS Nano. 2018 Aug 28;12(8):7812-7825. doi: 10.1021/acsnano.8b01890. Epub 2018 Jul 23.
2
Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.米托蒽醌。对其药效学和药代动力学特性以及在癌症化疗中的治疗潜力的综述。
Drugs. 1991 Mar;41(3):400-49. doi: 10.2165/00003495-199141030-00007.
Zotero 插件